Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTx-1301 in Adults With ADHD
NCT05631626Phase 3Completed
- Sponsor
- Cingulate Inc.
- Start
- Dec 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dexmethylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Cingulate Inc.. Started Dec 2022; status: completed.
02
Drugs
dexmethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT05631626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05631626.